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Abstract
Although the anti-cancer effects of curcumin has been shown in various cancer cell types, in vitro, pre-clinical and clinical
studies showed only a limited efficacy, even at high doses. This is presumably due to low bioavailability in both plasma and
tissues, particularly due to poor intracellular accumulation. A variety of methods have been developed to achieve the
selective targeting of drugs to cells and mitochondrion. We used a novel approach by conjugation of curcumin to lipophilic
triphenylphosphonium (TPP) cation to facilitate delivery of curcumin to mitochondria. TPP is selectively taken up by
mitochondria driven by the membrane potential by several hundred folds. In this study, three mitocurcuminoids
(mitocurcuminoids-1, 2, and 3) were successfully synthesized by tagging TPP to curcumin at different positions. ESI-MS
analysis showed significantly higher uptake of the mitocurcuminoids in mitochondria as compared to curcumin in MCF-7
breast cancer cells. All three mitocurcuminoids exhibited significant cytotoxicity to MCF-7, MDA-MB-231, SKNSH, DU-145,
and HeLa cancer cells with minimal effect on normal mammary epithelial cells (MCF-10A). The IC50 was much lower for
mitocurcuminoids when compared to curcumin. The mitocurcuminoids induced significant ROS generation, a drop in DØm,
cell-cycle arrest and apoptosis. They inhibited Akt and STAT3 phosphorylation and increased ERK phosphorylation.
Mitocurcuminoids also showed upregulation of pro-apoptotic BNIP3 expression. In conclusion, the results of this study
indicated that mitocurcuminoids show substantial promise for further development as a potential agent for the treatment
of various cancers.
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Introduction
Curcumin has been shown to exhibit anti-inflammatory,
antimutagenic, anticancer and antioxidant properties [1,2]. It
has been well established that curcumin inhibits the proliferation
and survival of almost all types of tumor cells [3]. Curcumin
induces cell-cycle arrest at G1/S or G2/M phases by inhibiting
the expressions of cyclin D1 or cdc2/cyclin B, respectively. The
major mechanism by which curcumin induces cytotoxicity in
tumor cells is by the induction of apoptosis through mitochondrial
pathway involving caspase-8, BID cleavage, cytochrome c release,
and activation of caspase-3. The proapoptotic members of the Bcl-
2 family, such as Bax, are activated, and antiapoptotic genes such
as Bcl-XL are inhibited by curcumin [4]. In our earlier studies, we
have demonstrated that curcumin and curcumin analogs exhibited
significant growth arrest and apoptosis in a number of human
cancer cell lines including breast, ovarian, and prostate cancer
with no apparent toxicity to noncancerous cells [5–7]. The
apoptosis induced by curcumin in tumor cells is mediated by
multiple signaling pathways that include p53, NF-kB, Akt and
JAK-STAT pathways [3].
BNIP3 (Bcl-2/adenovirus E1B 19 kDa-interacting protein3) is a
pro-apoptotic member of the Bcl-2 family of apoptotic proteins
and it is localized primarily in the mitochondrial outer membrane
[8]. Overexpression of BNIP3 leads to the activation of Bax/Bak,
opening of the mitochondrial permeability transition pore, and cell
death [9]. BNIP3 functions as a mitochondrial sensor of oxidative
stress, where an increase in ROS induces the homodimerization
and activation of BNIP3 via a conserved cysteine residue in the
NH2 terminus [10]. Recent studies suggest that curcumin plays a
role in cancer epigenetics through its interaction with histone
deactylases, histone acetyl transferases, DNA methyl transferases
and micro RNAs [11].
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Although the curcumin has been shown to exhibit anticancer
efficacy in various cancer cell types in vitro, its efficacy in pre-
clinical and clinical studies is limited, even at high doses. This is
presumably due to its poor water-solubility and short biological
half-life, resulting in low bioavailability in both plasma and tissues
[12]. To overcome these limitations, several approaches, including
combination of curcumin with adjuvants (e.g., piperine), and the
development of delivery vehicles consisting of liposomes, nano-
particles, phospholipid formulations and synthetic curcumin
analogs have been tested in vitro [12].
Mitochondria of cancer cells and transformed cells have
significantly higher transmembrane potential than normal cells
[13]. This biological property has been used as a basis to develop
compounds that may preferentially accumulate within the
mitochondria of cancer cells for selective targeting of drugs to
mitochondrion. One such approach to deliver to mitochondria is
by coupling of curcumin to lipophilic triphenylphosphonium
(TPP) cation. TPP is selectively taken up by mitochondria because
of its high negative membrane potential (140–170 mV, negative
side) [14]. Based on this observation, the TPP cation has been used
as a targeting moiety for delivery of agents such as spin traps,
fluorescence dyes, and antioxidants to isolated mitochondria, as
well as the mitochondria of intact cells and whole organisms [15].
The aim of this study was (i) to synthesize mitochondrially-targeted
curcuminoids, termed as mitocurcuminoids, to enhance the
intracellular/mitochondrial uptake of curcumin, (ii) to study the
anticancer efficacy of these compounds and (iii) to derive
mechanistic insights into the action of mitocurcuminoids. Since
ROS generation and alterations in mitochondrial membrane
potential may influence BNIP3 expression, the effect of mitocur-
cuminoid on the expression of BNIP3 and the epigenetic
alterations influencing BNIP3 expression by mitocurcuminoid
were also studied.
Materials and Methods
Curcumin (1,7-bis[4-hydroxy-3-methoxyphenyl]-1,6-hepta-
diene-3,5-dione) and triphenyl-phosphine were procured from
Sigma-Aldrich (USA). Synthesis of mitocurcuminoids-1, 2 and 3
(now referred as mitocur-1, mitocur-2 or mitocur-3) and charac-
terization are provided in File S1. Stock solutions of 2–100 mM
curcumin and mitocurcuminoids were prepared in DMSO and
stored at 220uC.
Cancer Cell Cultures
MCF-7 human breast cancer cell line was used for most of the
studies reported in this work. The other cancer cell lines used were
MDA-MB-231, SK-N-SH, DU-145, and HeLa. All cell lines were
obtained from ATCC. MCF-7 and MDA-MB-231 cells were
grown in DMEM supplemented with 10% FBS, 2% sodium
pyruvate, non-essential amino acids (2 mM), penicillin (100 units/
ml), streptomycin (100 mg/ml), and glutamine (4 mM). SK-N-SH,
DU-145, and HeLa cells were grown in MEM. Normal mammary
epithelial cells (MCF-10A) were grown in MEBM supplemented
with BPE, hEGF, insulin and hydrocortisone. Cells were grown to
70% confluence at 37uC in a humidified atmosphere of 5% CO2
and 95% air.
Cell Counting
Untreated and mitocucuminoid-1, 2, 3 or curcumin-treated
cells were counted using a Countess automated cell counter
(Invitrogen).
Isolation of cytosolic and mitochondrial fractions from
MCF-7 cells
MCF-7 cells were grown in 90-mm dishes, and then treated
with or without 10 mM of Mitocur-1, 2, 3 or curcumin for 6 h.
After the treatment, cells were washed thrice with PBS. The
isolation of mitochondrial and cytosolic extracts was carried out
using a commercially available ProteoExtract Cytosol/Mitochon-
dria Fractionation Kit (Merck, USA) according to manufacturer’s
instructions.
Detection and quantification of Mitocur-1, 2, and 3 in
MCF-7 cell extracts by Mass Spectrometry
The electrospray ionization (ESI)-MS (positive mode) measure-
ments were performed using a quadrupole time-of-flight mass
spectrometer (QSTAR XL, Applied Biosystems/MDS Sciex,
Foster City, CA, USA). The data acquisition was under the
control of Analyst QS software (Applied Biosystems). For the CID
(collision-induced dissociation) experiments, the precursor ions
were selected using the quadrupole analyzer and the product ions
were analyzed using the TOF analyzer.
The mitochondrial/cytosolic extracts (50 ml) were diluted with
50 ml of methanol, and introduced into the ESI source by flow
injection (10 ml loop) using methanol as the mobile phase at the
flow rate of 30 ml/min. Stock solutions (1 mM) of all the standards
were made in methanol:water (75:25, v/v), and a drop of DMSO,
if required, was used to dissolve the compound. For spiking
experiments, appropriate volumes of standard solutions (1–50 mM)
were added to the mitochondrial/cytosolic extracts of untreated
cells.
Sulforhodamine B (SRB) assay
Cells were grown in 24-well plates and treated with various
concentrations (0.1–50 mM) of Mitocur-1, 2, 3 or curcumin and
also with triphenylphosphonium (TPP) for a period of 24 h. The
cell viability was assessed by using SRB assay [16].
Detection of intracellular superoxide
MCF-7 cells were treated with Mitocur-1 (10 mM) or curcumin
(50 mM) for 4 h with and without antioxidant, N-acetyl cysteine
(NAC, 4 mM). After the treatment, cells were incubated with
10 mM DHE, for 30 min. Cells were then washed with PBS and
fluorescence images were immediately captured with a Nikon
Eclipse TE2000-U camera system using excitation/emission at
488/585 nm. Images were analyzed using MetaMorph image
analysis software. Further the ROS generation by Mitocur-1 or
curcumin in MCF-7 cells was determined by EPR spectroscopy
(for procedure see File S1).
Cell-cycle analysis by Flow cytometry
For DNA content analysis, MCF-7 cells were treated with
Mitocur-1 (10 mM) for 24 h. Cells were harvested and centrifuged
for 5 min at 300 g, fixed by the gradual addition of ice cold 70%
ethanol and washed with PBS. Cells were then treated with RNase
(10 mg/ml) for 30 min at 37uC, washed twice with PBS, and
resuspended and stained with 1 ml of propidium iodide (69 mM)
containing 38 mM sodium citrate for 30 min at room temperature
[17]. The cell cycle phase distribution was determined and the
percentage of cells in each phase of the cell cycle was analyzed
using ModFit LT software (BectonDickinson).
Detection of mitochondrial transmembrane potential
Mitochondrial potential was assessed using the fluorescent
potentiometric dye JC-1 (5,59,6,69-tetrachloro-1,19, 3, 39-tetra-
Mitochondrial-Targeted Curcuminoids
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ethylbenzimidazolcarbocyanine iodide) (Molecular Probes, Eu-
gene, OR). In healthy cells, JC-1 forms J-aggregates that display a
strong red fluorescence with excitation of 560 nm and emission
wavelength at 595 nm. In apoptotic or unhealthy cells, JC-1 exists
as monomers that display a strong green fluorescence with
excitation and emission at 485 nm and 535 nm, respectively.
MCF-7 cells were treated with Mitocurc-1, 2, or 3 for 4 h. At the
end of the treatments, cells were washed with DPBS, incubated
with JC-1 dye (5 mg/ml) for 20 min and observed under the
fluorescence microscope.
Caspase 3-like and caspase 8 activity
MCF-7 cells were treated with Mitocur-1 (5 mM) or curcumin
(5 mM) for 24 h. Cells were then washed twice in cold DPBS and
lysed in buffer containing 10-mM Tris-HCl, 10-mM NaH2PO4/
Na2HPO4 pH.7.5, 130-mM NaCl, 1% Triton, and 10-mM
sodium pyrophosphate. Cell lysates were incubated with caspase 3
fluorogenic substrate, N-acetyl-Asp-Glu-Val-Asp-7-amido-4-
methylcoumarin, or caspase 8 fluorogenic substrate, N-acetyl-
Ileu-Glu-Thr-Asp-7 amido-4-methylcoumarin (Sigma) at 37uC for
1 h. The 7-amido-4-methyl-coumarin liberated from the substrate
was measured using a fluorescence plate reader (Tecan M-200)
with lex = 380 nm and lem = 460 nm.
Western blot analysis
After the treatments with either curcumin or with Mitocur-1 for
24 h, MCF-7 cells were lysed in RIPA buffer containing protease
and phosphatase-inhibitor cocktail and centrifuged at 10,000 rpm
for 20 min at 4uC and supernatant was collected and proteins
were resolved by SDS–PAGE, blotted onto a nitrocellulose
membrane and incubated with Bcl2, Bax, caspase-7, PARP,
cyclin B1, cyclin A, cyclin D1, pSTAT(Tyr-705), STAT, pAkt
(Thr-308), Akt, pERK1/2, ERK antibodies in separate experi-
ments. The detection was carried out with either HRP-labeled
sheep anti-mouse IgG or HRP-labeled donkey anti-rabbit IgG
(Amersham) using an enhanced chemiluminescence detection
system (ECL Advanced Kit, GE Health care).
BNIP3 expression by RT-PCR
Total RNA was isolated from MCF-7 using TRIzol method
according to manufacturer’s instructions (Invitrogen). Quantitative
RT-PCR was performed using gene specific forward (FP) and
reverse primers (RP) of BNIP3(FP:59CCACCTCGCTCGCAGA-
CACCAC39, RP:59GAGAGCAGCAGAGATGGAAGGAAA-
AC39) respectively.
Statistical analysis
Data are expressed as mean 6 SD. Comparisons among the
groups were performed using Student- t test. The significance level
was set at p,0.01. IC50 was measured from logarithmic regression
equation of dose versus percentage of inhibition cell proliferation.
Results
The synthesis, structural analysis of Mitocur-1, 2, and 3 and
their cellular uptake (Fig. S1, S2, S3, S4, S5, S6, S7) in MCF-7
cells are shown in supporting information. Fig. 1 shows the
structures of Mitocur-1, 2, and 3. HRMS data of these compounds
is shown in Table S1 in File S1.
Quantification of Mitocur-1, 2 or 3 in mitochondrial/
cytosolic fractions of MCF-7 cells
Standard calibration curve (Fig. S4, S5, S6, S7) for each
compound (Mitocur-1, 2, or 3) was constructed using the ion
counts of the respective peaks in the spectra of spiked samples
(average of triplicate data). The quantities of the mitocurcuminoids
from the extracts of treated cells were obtained using the ion count
Figure 1. Chemical structure of the mitochondria-targeted
curcuminoids used in this study. (A) Curcumin; (B) Mitocur-1; (C)
Mitocur-2; (D) Mitocur-3. The synthetic curcuminoids (Mitocur-1,2,3)
have a triphenylphosphonium cation linked to the hydroxyl group(s) of
curcumin via a three-carbon propyl chain. Mitocur-3 is similar to
Mitocur-1, but is devoid of methoxy substitution on the aryl groups.
doi:10.1371/journal.pone.0089351.g001
Table 1. Cellular uptake of curcumin and mitocurcuminoids-1, 2, and 3.
Compound Mitochondrial fraction (n mol/mg protein) Cytosolic fraction (n mol/mg protein)
Curcumin ND 89610
Mitocur-1 16806106 164632
Mitocur-2 670698 184638
Mitocur-3 14746162 178610
MCF-7 cells were treated with either curcumin (10 mM) or Mitocur-1, 2, 3 (10 mM) respectively for a period of 6 h. Mitochondrial and cytosolic fractions were isolated as
described in Methods section. Values represented are Mean6SD of three independent experiments.
doi:10.1371/journal.pone.0089351.t001
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Table 2. Curcumin and Mitocur-1, 2 and 3 induce cell death in various cancer cells by SRB Assay.
Compound MCF-7 IC50 (mM) MDA-MB-231 IC50 (mM) HeLa IC50 (mM) DU-145 IC50 (mM) SKNSH IC50 (mM)
Curcumin 40.32 37.87 48.07 50 38.46
Mitocur-1 2.31 5.1 4.46 5.10 5.12
Mitocur-2 5.31 8.33 7.69 8.62 8.19
Mitocur-3 3.84 6.75 4.38 6.75 6.28
MCF-7, MDA-MB-231, HeLa, DU-145, and SKNSH cells were incubated with curcumin, mitocurcuminoids-1, 2, or 3 at a dose ranging from 0.1–50 mM for a period of 24 h.
At the end of the treatments, cell death was assayed by SRB assay as described in Methods section. Results are expressed as IC50 (mM). Values represent data in triplicates
from at least three independent experiments.
doi:10.1371/journal.pone.0089351.t002
Figure 2. Mitocur-1, 2 and 3 induces superoxide generation in MCF-7 cells. (A) Ethidium fluorescence of MCF-7 cells treated with curcumin
(50 mM) and mitocur-1, 2, 3 (10 mM) for 4 h. All experiments were performed with and without NAC (4 mM). Representative fluorescence images are
shown. (B) shows quantification of fluorescence intensities shown in A. **, significantly different compared to control (P,0.01) and #, significantly
different compared to mitocurcuminoid-1, 2 and 3 (P,0.01). (C) cells were treated with or without 10 mM mitocurcuminoid-1 and 4 mM NAC for
24 h. Results are expressed percentage of viable cells compared to control. Data represented is from at least three independent experiments. **,
significantly different compared to control (P,0.01) and #, significantly different compared to NAC (P,0.01).
doi:10.1371/journal.pone.0089351.g002
Mitochondrial-Targeted Curcuminoids
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of the particular ion and the linear regression equation of the
calibration curve (Table 1 and Fig. S4, S5, S6, S7). Table 1 clearly
shows that the accumulation of mitocurcuminoids in mitochondria
more than in cytosol. Also, Mitocur-1 and 3 accumulated more in
the mitochondrial fraction of MCF-7 cells as compared to
Mitocur-2 that could be due to the presence of two TPP tags at
either side of the curcumin molecule (Table 1).
Mitocurcuminoids (1, 2, or 3) are significantly toxic to
MCF-7, MDA-MB-231, DU-145, HeLa and SKNSH cells
The cytotoxic effects of mitocurcuminoids were determined and
compared with that of free curcumin and TPP in MCF-7, MDA-
MB-231, HeLa, DU-145, and SK-N-SH cells. The IC50 values are
presented in Table 2. Among the different cancer cell lines tested,
it was observed that MCF-7 cells were the most susceptible to
mitocurcuminoid-induced cell death. Of the mitocurcuminoids,
Mitocur-1 was found to be more potent and for this reason, all the
subsequent studies to understand the mechanistic aspects of
mitocurcuminoid-induced cancer cell death were carried out in
MCF-7 cells. Nevertheless, compared to free curcumin, all three
mitocurcuminoids showed significant cytotoxicity to all the cancer
cell lines tested in this study (Table 2).
The cytotoxic effects of mitocurcuminoids were also studied in
normal mammary epithelial cells (MCF-10A). The results (Fig. S8)
shows that there was no significant effect of mitocurcuminoids on
MCF-10A cells. Separate experiments were performed on the
cytotoxic effect of TPP alone on MCF-7 breast cancer cells. TPP
was tested at different concentrations (1, 5 10 mM) for 24 h and
the results showed no toxicity of TPP alone (Fig. S9)
Mitocurcuminoids induces ROS generation in MCF-7 cells
MCF-7 cells treated with the mitocurcuminoids (at 10 mM for
4 h) showed significant increase in ethidene fluorescence as an
indicator of superoxide generation (Fig. 2A–B). This increase in
ethidine fluorescence was significantly abrogated in cells pretreat-
ed with N-acetylcysteine (NAC, 4 mM). The inhibition of ROS
generation by NAC was also evident from the cell-viability
measurements, which showed significant inhibition of the cyto-
toxic effects induced by Mitocur-1 (Fig. 2C).
Mitocur-1 generates superoxide in MCF-7 cells
The superoxide generation by Mitocur-1 in MCF-7 cells was
further confirmed by EPR spectroscopy using DMPO spin-trap
agent. The EPR spectrum of MCF-7 cells treated with Mitocur-1
showed the presence of DMPO-OH adduct (Fig. 3). The origin of
the DMPO-OH adduct was confirmed to be superoxide using
Mn-TBAP, an intracellular superoxide scavenger. There was no
adduct formation in cells treated with curcumin at the tested
concentration.
Mitocur-1 induces loss of mitochondrial membrane
potential in MCF-7 cells
MCF-7 cells treated with Mitocur-1, 2, or 3 showed a
substantial reduction in the ratio of red to green fluorescence
(Fig. 4A). This indicates a drop in DYm. The untargeted curcumin
(50 mM) also did cause a marginal loss of mitochondrial
membrane potential. The quantification of J-aggregate fluores-
cence intensities of the same are shown in Fig. 4B. In tune with the
loss of mitochondrial membrane potential, both curcumin at
50 mM and mitocurcuminoid-1 at 5 and 10 mM appreciably
increased the release of cytochrome c into the cytosol (Fig. 4C).
Mitocur-1 treatment also significantly upregulated Bax and
downregulated Bcl-2 expressions (Fig. 4D), which are proapoptotic
and antiapoptotic proteins of Bcl family respectively. In line with
the above results, MCF-7 cells treated with Mitocur-1 also resulted
in the cleaved caspase-7 and degradation of PARP (Fig. 4D).
Mitocur-1 induces cell cycle arrest and causes cell death
by apoptosis pathway in MCF-7 cells
Among the three mitocurcuminoids studied, Mitocur-1 showed
significantly higher toxicity than the other two compounds. To see
whether the growth inhibition of MCF-7 cells by Mitocur-1 was
caused by cell-cycle arrest, we performed flow-cytometry analysis.
Cells were treated with Mitocur-1 for 24 h, fixed; and cell-cycle
populations were determined by flow cytometry (5A). The results
showed that cell population in the G2-M and sub-G1 phases were
significantly higher in the treatment group when compared to the
untreated control group (Fig. 5B). Mitocur-1 significantly down
regulated the cell-cycle regulatory proteins such as, Cyclin A, B1,
and, D1 as determined by Western-blot analysis (Fig. 5C). These
results indicated that Mitocur-1 modulates both G1/S and G2/M
cell-cycle proteins. To determine whether the Mitocur-1–induced
cell-cycle arrest led to apoptosis, caspase-3 and caspase-8 enzyme
activities were measured. It was observed that caspase-3 activity was
increased by 20-fold and caspase-8 by 4.5-fold in Mitocur-1 treated
cells as compared to untreated conditions (Table 3). Untargeted
curcumin also marginally induced both the caspase activities.
Mitocur-1 inhibits the STAT3, Akt and ERK pathways
Further, we have investigated whether mitocur-1–induced cell
death of MCF-7 cells is mediated by alterations in Akt (Thr-308),
STAT3 (Tyr-703) and ERK1/2 (P42/44, Thr202/Tyr 204)
phosphorylation statuses. It was found that STAT3 and Akt
phosphorylations were decreased but whereas ERK phosphoryla-
tion increased significantly in MCF-7 cells treated with Mitocur-1
(10 mM) for a period of 24 h (Fig. 6). The observed results with
decreased phosphorylation of STAT3 are in line with the altered
expressions of some of the known downstream targets of STAT3
including Bcl2 and Bax as shown in Fig. 6.
Figure 3. Superoxide generation in MCF-7 cells treated with
mitocur-1 detected by EPR spectroscopy using DMPO spin
trap. (A) Cells alone; (B) Cells+curcumin (10 mM); (C) Cells+mitocur-
1Mitocur- (10 mM); (D) Cells+mMitocur-1 (10 mM)+MnTBAP (10 mM); (E)
xanthine+xanthine oxidase. Microwave frequency, 9.786 GHz; micro-
wave power, 10 mW; modulation amplitude, 1 G; scan time, 30 s; no. of
scans, 10.
doi:10.1371/journal.pone.0089351.g003
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Mitocur-1 regulates BNIP3 expression possibly via
altering DNMT
Mitocur-1 at sub-micromolar concentrations (5–10 mM) in-
duced BNIP3 expression in MCF-7 cells treated for 24 h.
Compared to baseline expression of BNIP3 in MCF-7 cells,
treatment of Mitocur-1, showed a significant increase in the
BNIP3 expression (Fig. 7A). To study the role of DNA methylation
and histone deacetylation on BNIP3 expression, specific inhibitors
Figure 4. Effect of mitocurcuminoids and curcumin on mitochondrial membrane potential and apoptotic markers. (A) Cells were
treated with 10 mM Mitocur-1, 2, 3 or 50 mM curcumin for 4 h. Then washed with PBS and incubated with JC-1 dye (5 mg/ml) for 20 min to measure
the loss of mitochondrial membrane potential. Fluorescence images were captured in both FITC and rhodamine filters and images showing J-
aggregates are represented. (B) shows quantification of images (J-aggregates) shown in A. (C) Mitochondria and cytosolic fractions were isolated
using ProteoExtract Cytosol/Mitochondria Fractionation Kit and cytochrome c levels were measured by Western blot analysis. (D) MCF-7 cells were
treated with Mitocur-1 (5 and 10 mM) for 24 h. Total protein was resolved by SDS-PAGE electrophoresis and Western blot analysis was performed
using respective antibodies for Bcl2, Bax, caspase-7 and PARP. **, significantly different compared to control (p,0.01).
doi:10.1371/journal.pone.0089351.g004
Mitochondrial-Targeted Curcuminoids
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such as 5-Aza-29deoxycytidine (AZA), a specific inhibitor of DNA
methyltransferase and trichostatin A (TSA), an inhibitor of class 1
and II of histone deacetylases, were used. Treatment of MCF-7
cells with AZA showed an increased expression of BNIP3,
suggesting a role for DNA methylation in influencing BNIP3
expression (Fig. 7B). The role of histone acetylation in controlling
BNIP3 expression was ruled out by treating the cells with TSA,
which did not alter the BNIP3 (Fig. 7C)
Discussion and Conclusion
In the current study, mitochondrially-targeted mitocurcumi-
noid-1, 2, and 3 were synthesized by covalently coupling curcumin
to lipophilic TPP cation and structures were confirmed by ESI-MS
and HRMS. Mitocur-1 and 3 were synthesized by tagging the
curcuminoid with two TPP moieties with the only difference being
the absence of a methoxy group in Mitocur-3. This was done to
see if the presence or absence of a methoxy group will affect the
uptake of the compound into the mitochondria. However, it was
found that the methoxy substitution did not affect the uptake.
When compared to curcumin, Mitocur-1, 2, and 3 accumulated
more effectively in the mitochondria of MCF-7 cells. Of the three
compounds, Mitocur-1 and 3 accumulated most significantly in
the mitochondria of MCF-7 cells as compared to Mitocur-2. The
reason for the increased uptake of Mitocur-1 and 3 into the
mitochondria could be due to the presence of two TPP moieties in
these molecules and hence more anti-proliferative effects in all the
cancer cell lines tested when compared to Mitocur-2 that has only
one TPP conjugation. Our results also indicate that the absence of
OH group in the Mitocur-1 or 3 does not affect their uptake and
cytotoxicity towards cancer cells. In a recent study, it was observed
that vitamin E analogs like mito-chromanols possessing phenolic
hydroxyl group and acetylated ester analog of mito-chromonals
lacking a free OH group showed equal potency in breast cancer
cells [18], indicating that presence of free OH group is not critical
in anticancer efficacy as observed in our study. Further, we tested
the effect of mitocurcuminoids on normal epithelial cells, MCF-
10A and found no toxicity. The mechanism of anticancer action of
Mitocur-1 was observed to be by multiple pathways; increased
generation of ROS, increased oxygen consumption (data not
shown) measured by using paramagnetic oxygen sensing probe,
LiNc-BuO by EPR spectroscopy [19], modulation of proteins
involved in G2/M cycle arrest, downregulation of antiapoptotic
signals and inhibition of Akt and STAT3 phosphorylation, and
increased ERK phoshorylation. The observed mechanism of
action of the mitocurcuminoids is similar to that of free curcumin
which was demonstrated by us [6] and others [20], indicating that
conjugation of TPP does not interfere with the anticancer
properties of curcumin. TPP alone showed no toxicity to MCF-7
breast cancer cells. Furthermore, this study, for the first time,
demonstrated that Mitocur-1 induced apoptosis, may also in part,
involve the upregulation of pro-apoptotic BNIP3, possibly by
modulating the regulation of DNA methyl transferase activities.
Several mitochondria-targeted drugs and antioxidants (Mito-Q,
Mito-CP, Mito-vitamin E, Mito-peroxidase, and Mito-PBN) have
been successfully synthesized and tested [21–24]. Studies using in
vivo animal models with oral administration of lipophilic
triphenylphosphonium cations demonstrated significant uptake
in liver, heart, and muscle [25]. A recent study reported that Mito-
Figure 5. Modulation of cell cycle progression by Mitocur-1. MCF-7 cells were treated with Mitocur-1 (5 and 10 mM) for a period of 24 h. (A)
shows the flow cytometry profiles of (PI)- stained cells of control, and Mitocur-1 (5 and 10 mM) treatment as described in Methods. (B) Quantitative
cell cycle (DNA content) distribution (% of total) in the control and treatment groups. (C) MCF-7 cells were treated with Mitocur-1 (5 and 10 mM) for
24 h and subjected to Western blot analysis. Representative immunoblot images of cyclin A, cyclin B1 and cyclin D1 are shown. Values are expressed
Mean 6 SD; (n = 4). **, significantly different from control (P,0.01).
doi:10.1371/journal.pone.0089351.g005
Table 3. Mitocur-1 increase caspase 3-like and caspase-8 activities in MCF-7 cells.
Sample Caspase 3-like activity (% control) Caspase-8 activity (% control)
Control 100 100
Curcumin (5 mM) 19066.69 17066.74
Mitocur-1 (5 mM) 192166.83 47966.50
MCF-7 cells were treated with either curcumin or Mitocur-1 for 24 h and caspase 3-like and caspase-8 activities were measured by using respective substrates as
mentioned in Methods. The fluorescence intensity was normalized to mg protein and the values are expressed as % control.
doi:10.1371/journal.pone.0089351.t003
Figure 6. Mitocur-1 causes inhibition of Akt and STAT3
signaling and increase the ERK1/2 phosphorylation. MCF-7 cells
were treated with Mitocur-1 (5 or 10 mM) for 16 h and subjected to
Western blot analysis as described in Methods. Representative
immunoblot images of STAT3, phosphorylated STAT3 (Tyr705), Akt,
phospho-Akt (Thr-308), ERK1/2 and phospho- ERK1/2 are shown.
doi:10.1371/journal.pone.0089351.g006
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Q was 30-fold more cytotoxic to breast cancer cells than to healthy
mammary cells [26]. Similarly, TPP-conjugated resveratrol
showed significant accumulation in mitochondria of cancer cells
and showed toxicity to cancer cells [27]. The present study
demonstrated that Mitocur-1 inhibited the MCF-7 breast cancer
cell proliferation by inducing G1/S and G2/M phase of the cell-
cycle arrest leading to apoptotic cell death. This was accompanied
by the downregulation of both cyclin-A and cyclin B1. Cyclin D1
is overexpressed in many cancers, including breast, esophagus,
head and neck, and prostate cancer [28]. Previous studies have
shown that curcumin blocks the proliferation of various cancer
cells by downregulating the expression of the cyclin D1 protein
[29,30].
In the current study, activation of caspase-8, caspase-7, caspase
3-like activities and cleavage of PARP was observed in MCF-7
cells treated with Mitocur-1 in inducing apoptosis and these results
are in agreement with earlier published reports on anti-cancer
effects of curcumin [30,31]. Recent work also showed that
curcumin inhibits growth and survival of human head and neck
squamous cell carcinoma cells via modulation of NF-kB signaling
[32]. It is well established that an increase in ROS levels, drop in
DØm may activate apoptosis through caspase-3 activation and
cytochrome c release. There was an increase in translocation of
mitochondrial cytochrome c into the cytosol in cells treated with
Mitocur-1 suggesting that TPP-tagged curcuminoids induce
mitochondria-dependent pathway of apoptosis.
Akt plays critical roles in mammalian cell-survival signaling and
is active in various cancers. The present study showed that
mitocurcuminoid dose dependently decreased Akt phosphoryla-
tion (Thr-308) in MCF-7 cells. These results indicate a possibility
that mitocurcuminoids activate protein phosphatase 2A (PP2A)
activity that in turn enhances the dephosphorylation of Akt at Thr-
308 as shown previously [33].
STAT3 is also known to protect cells from apoptosis through
the upregulation of Bcl-xL, Bcl-2, and survivin. Elevated STAT3
activity has been detected in head and neck squamous cell
carcinoma, leukemia, lymphoma and multiple myeloma [34,35].
In the current study, Mitocur-1 inhibited the STAT3 phosphor-
ylation and downstream targets such as Bcl2 and Bax in MCF-
cells. Parent curcumin has been shown to reduce the STAT3
Figure 7. Curcumin and Mitocur-1 presumably regulates BNIP3 expression by modulating DNMT1 but not through HDAC’s. (A) MCF-
7 cells were treated with various concentrations of either mitocurcuminoid-1 (1–10 mM) or curcumin (5–50 mM) for a period of 24 h. Total RNA was
extracted by TRIzol method and RT-PCR was performed using gene specific primers of BNIP3. (B) and (C) are same as A, except that cells were treated
with AZA, (24 mM) or TSA (200 nM). Relative quantifications of BNIP3 expressions were presented in bar graphs. *, significantly different compared to
control (p,0.01).
doi:10.1371/journal.pone.0089351.g007
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phosphorylation in a variety of cancer cells, however at relatively
higher concentrations [34,35].
In the current study, we observed that Mitocur-1 activates
ERK1/2 phosphorylation in MCF-7 cells. Earlier, it was shown
that curcumin inhibits the Akt/mTOR/p70S6K pathway and
activated the ERK1/2 pathway simultaneously [36]. Curcumin
can also act as potent radiosensitizer and cause a significant
generation of ROS that further lead to the activation of ERK [36].
The increase in ROS by Mitocur-1, as observed in this study, may
have lead to activation of ERK1/2 phosphorylation and
subsequently the induction of pro-apoptotic pathway.
BNIP3, a pro-apoptotic member of the Bcl-2 family, is being
explored in relation to apoptosis and cancer cell death. The
increase in BNIP3 by mitocurcuminoids-1 may be presumably due
to increase in oxidative stress and a drop in DØm. Expression of
BNIP3 is associated with the mitochondrial permeability transition
(MPT). In a recent study, we have demonstrated a linear
relationship between oxidative DNA damage marker, 8-oxodG
and BNIP3 expression [37]. It has also been demonstrated that
BNIP3 may act as a mitochondrial sensor of oxidative stress [10].
When activated, BNIP3 changes mitochondrial membrane
potential, leading to generation of ROS. In the present study,
BNIP3 expression was studied by using specific inhibitors of
DNMT and HDACs such as AZA and TSA. AZA-treated cells
showed increased expression of BNIP3 in MCF-7 cells. However,
TSA-treated cells showed no alteration in the expression of
BNIP3. It appears that the increase in BNIP3 expression by
Mitocur-1 may modulate the DNA methylation mechanisms.
However, the epigenetic regulation of increased expression of
BNIP3 by mitocurcuminoids\ requires further investigation. In a
recent study, we observed that breast tumors exhibiting hypo-
methylation of BNIP3 had elevated 8-oxodG compared to tumors
exhibiting intermediate to high level of methylation [38].
Differential methylation patterns were reported across different
cancer cell lines where in certain cell lines exhibited hypermethy-
lation of BNIP3 associated with its silencing [39,40]. However,
there is no concluding link of this BNIP3 hypermethylation with
cytotoxicity. In a recent study, we have shown that HAEC cells
lack BNIP3 expression, which was restored upon treatment with 5-
aza cytidine concluding that hypermethylation is associated with
silencing of BNIP3 [41].
In summary, this study demonstrated that conjugation of
curcuminoids with TPP cation, showed significant accumulation
in mitochondria in MCF-7 cells. Mitocur-1 induced ROS
generation, a drop in DØm, and inhibited cell proliferation by
inducing cell-cycle arrest leading to apoptotic cell death. Although
it was seen that mitocurcuminoid treatment greatly enhanced the
generation of ROS, at this time we do not know the mechanisms
involved in this process. However, it was observed that
mitocurcuminoid-induced generation of ROS and cell death is
significantly attenuated in the presence of NAC, thereby
suggesting that oxidative stress at least, in part plays a role in
mitocurcumiod-mediated cancer cell death.
Further, the inhibition of proliferation was mediated through
the inhibition of Akt and STAT3 phosphorylation, and activation
of ERK1/2 phosphorylation. Overall, it appears that curcumin
can alter several phosphorylation events involved in various
cellular processes. This study further highlights two important
mechanisms by which Mitocur-1 induces increased expression of
BNIP3 namely by (i) induction of ROS and a drop in DØm, and
(ii) methylation of BNIP3 promoter. Studies utilizing animal
models are warranted in order to study the uptake, distribution
and efficacy of these mitochondrially-targeted curcuminoids
against various animal tumor models.
Supporting Information
File S1 A, Synthesis of Mitocurcuminoids-1, 2 and 3; B,
Determination of superoxide using EPR spectroscopy C, Struc-
tural analysis of mitocurcuminoid-1, 2, & 3; D, Cellular uptake of
mitocurcuminoid-1, 2, 3 or curcumin by MCF-7 cells.
(DOCX)
Table S1 High Resolution Mass Spectrophotometry
(HRMS) data for curcumin, mitocurcuminoid-1, 2, and
3.
(PDF)
Figure S1 Synthetic scheme of mitocurcuminoid-1.
(TIF)
Figure S2 The ESI-MS spectra of A, Curcumin; B,
Mitocurcuminoid-1; C, Mitocurcuminoid- 2; D, Mitocurcumi-
noid-3.
(TIF)
Figure S3 The ESI-MS/MS spectra fragmentation pat-
tern of curcumin and mitocurcuminoids. A, Curcumin (m/
z 369; CE=35 eV); B, Mitocurcuminoid-1 (m/z 487;
CE=35 eV); C, Mitocurcuminoid-2 (m/z 671; CE=35 eV); D,
Mitocurcuminoid3(m/z457;CE=40 eV).
(TIF)
Figure S4 ESI-MS spectra of curcumin (10 mM) treated
MCF -7 cells. A, cytosolic fraction and B, mitochondrial fraction.
Insert shows the calibration curve of mitocurcuminoid-1 (10 mM)
treated MCF-7 cells: cytosolic fraction and mitochondrial fraction.
Value corresponding to each point is an average of triplicate
measurements made on different days. The error bars in the figure
represent the standard deviations from three triplicate measure-
ments.
(TIF)
Figure S5 ESI-MS spectra of mitocurcuminod-1 (10 mM)
treated MCF-7 cells. A, cytosolic fraction and B, mitochondrial
fraction. . Insert shows the calibration curve of Mitocurcuminoid-2
(10 mM) treated MCF cells: cytosolic fraction and mitochondrial
fraction. Value corresponding to each point is an average of
triplicate measurements made on different days. The error bars in
the figure represent the standard deviations from three triplicate
measurements.
(TIF)
Figure S6 ESI-MS spectra of mitocurcuminoid-2
(10 mM) treated MCF-7 cells. A, cytosolic fraction and B,
mitochondrial fraction. Insert shows the calibration curve of
mitocurcuminoid-3 (10 mM) treated MCF cells: cytosolic fraction
and mitochondrial fraction. Value corresponding to each point is
an average of triplicate measurements made on different days. The
error bars in the figure represent the standard deviations from
three triplicate measurements.
(TIF)
Figure S7 ESI-MS spectra of mitocurcuminoid-3
(10 mM) treated MCF cells. A, cytosolic fraction and B,
mitochondrial fraction. Insert shows the calibration curve of
curcumin (10 mM) treated MCF cells: cytosolic fraction. Value
corresponding to each point is an average of triplicate measure-
ments made on different days. The error bars in the figure
represent the standard deviations from three triplicate measure-
ments.
(TIF)
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Figure S8 Cell Viability of MCF-10A treated with
various concentrations of curcumin and mitocurcumi-
noids. MCF-10A cells were incubated with various concentra-
tions of curcumin and mitocurcuminoids-1, 2 and 3 for 24 h. At
the end of treatments, cell viability was assayed by SRB assay.
(TIF)
Figure S9 Cell Viability of MCF-10A treated with
various concertrations of triphenylphosphonium
(TPP+). MCF-7 cells were incubated with various concentrations
of TPP+ for 24 h. At the end of treatments, cell viability was
assayed by SRB assay.
(TIF)
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